Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Inventiva S.A.NASDAQ: IVA

Gross Profit · Q4 FY2025 · quarter ended Dec 2025

Gross profit turns negative

Q4 FY2025 gross profit was -€1.17M, compared with €6.99M a year earlier. Over 3 fiscal years it compounded at -55.4% a year.

Context

  • Gross profit amounted to 33.7% of revenue in FY2025, down 66.3 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-€1.17M— QoQ
Last fiscal yearDec 2025
€1.51M-83.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-116.7%——
1 year-83.6%——
3-year CAGR-55.4%——
5-year CAGR——
10-year CAGR——

Gross Profit history

EUR · from the income statement

Latest · FY2025
1.51M EUR
Year-over-year change
-83.6%
4-year CAGR
-22.5%

Gross Profit vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -83.6% is the 8th highest of 10, against a peer median of +43.5%.
  • Gross profit amounts to 33.7% of revenue for IVA, versus a peer median of 99.3%.
IVA Competitors
Gross Profit for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$68M USD+5.5%-11.0%98.3%
IVVDInvivyd, Inc.LTM Mar 2026$51.41M USD+50.2%—92.0%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$32.49M USD+1115.8%+118.1%99.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$9.26M USD+117.7%-9.7%82.6%
IVAInventiva S.A.FY2025€1.51M EUR-83.6%-55.4%33.7%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$326K USD+115.4%—144.9%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$151.18K USD-13.6%——
NAUTNautilus Biotechnology, Inc.LTM Mar 2026-$6.32M USD+43.5%——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$10.62M USD-104.7%-84.1%17996.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$11.02M USD-132.3%-70.5%621.0%
Peer median (excluding IVA) —+43.5%-11.0%99.3%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.19M12.18M17.48M9.2M4.48M
Cost of Revenue1.02M995K(23K)3.88M2.8M
Gross Profit4.19M17.06M17.5M9.2M1.51M
Gross Margin100.0%140.1%100.1%100.0%33.7%
Research & Development48.45M60.47M110.01M90.88M83.61M
Selling, General & Admin11.52M15.5M15.61M17.1M53.89M
Operating Expenses56.31M74.17M120.19M106.76M137.37M
Depreciation & Amortization858K870K2.6M5.2M2.8M
EBITDA(52.76M)(56.29M)(102.04M)(166.53M)(128.15M)
EBITDA Margin-1258.0%-462.2%-583.9%-1810.4%-2858.6%
Operating Income(52.11M)(57.11M)(102.71M)(97.56M)(130.95M)
Operating Margin-1242.6%-468.9%-587.7%-1060.6%-2921.0%
Interest Income57K390K945K1.14M2.83M
Interest Expense138K707K5.18M12.18M32.3M
Other Income / Expenses2.84M2.82M(7.11M)(86.34M)(211.38M)
Income Before Tax(49.27M)(54.29M)(109.82M)(183.9M)(342.33M)
Pre-Tax Margin-1174.8%-445.8%-628.4%-1999.4%-7636.1%
Income Tax Expense364K(20K)607K313K22K
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Net Margin-1183.5%-445.6%-631.8%-2002.7%-7587.8%
EPS (Basic)(1.27)(1.31)(2.43)(3.54)(1.82)
EPS (Diluted)(1.27)(1.31)(2.43)(3.54)(1.82)
Weighted Avg Shares39.17M41.45M45.35M51.98M186.8M
Weighted Avg Shares (Diluted)39.17M41.45M45.35M51.98M186.8M

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.